BioSyent Inc (RX-X) Stock Predictions - Stockchase
WATCH LIST
21
BioSyent Inc (RX-X)

ON STOCKCHASE SINCE Mar 2014

Consumer Products

BioSyent Inc

RX-X

10 watching          
Join the Discussion

BioSyent Inc (RX-X) SAVE Apr, 24, 2019, 12:35 pm

7.46 0.02 (0.27%)

What the experts are saying about RX-X



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
BioSyent Inc(RX-X) 

April 12, 2018

(A Top Pick March 29/17, Up 33%)  They license health care products from outside of Canada.  They have been very good at providing consistent return on equity as well as earnings growth.  This year will be an interesting time.  They are sitting on almost $20 Million as a war chest and adding to it every quarter.  They are searching for opportunities and will be diligent in deploying it.  They are an under the radar company.

Consumer Products
0 0 0 0 0
0 comments

(A Top Pick March 29/17, Up 33%)  They license health care products from outside of Canada.  They have been very good at providing consistent return on equity as well as earnings growth.  This year will be an interesting time.  They are sitting on almost $20 Million as a war chest and adding to it every quarter.  They are searching for opportunities and will be diligent in deploying it.  They are an under the radar company.

Consumer Products
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$10.000
Owned Owned
Yes

PAST TOP PICK
BioSyent Inc(RX-X) 

July 10, 2017

(A Top Pick July 4/16. Up 4.26%.) They in-license products from companies that don’t have a marketing presence of pharmaceutical products in Canada. A very, very well-run company. A nice ROE at just under 30%. Have 2 new cardiology products that should be coming online towards the end of 2018-2019. No debt and about $14 million in cash.

Consumer Products
0 0 0 0 0
0 comments

(A Top Pick July 4/16. Up 4.26%.) They in-license products from companies that don’t have a marketing presence of pharmaceutical products in Canada. A very, very well-run company. A nice ROE at just under 30%. Have 2 new cardiology products that should be coming online towards the end of 2018-2019. No debt and about $14 million in cash.

Consumer Products
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$8.550
Owned Owned
Yes

TOP PICK
BioSyent Inc(RX-X) 

March 29, 2017

A pharma company, but not one that does research and trials.  They license products.  Their CEO is excellent and they are a very well run company.  Growth will come from their existing product suite plus additionally 3 more products.  They are active on the business development front.  (Analysts’ target: $9.13).

Consumer Products
0 0 0 0 0
0 comments

A pharma company, but not one that does research and trials.  They license products.  Their CEO is excellent and they are a very well run company.  Growth will come from their existing product suite plus additionally 3 more products.  They are active on the business development front.  (Analysts’ target: $9.13).

Consumer Products
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$7.500
Owned Owned
Yes

PAST TOP PICK
BioSyent Inc(RX-X) 

January 24, 2017

(A Top Pick July 4/16. Down 10.97%.) This in-licenses products and solutions from companies that are generally situated in Europe. They generally bring in in-licenses for companies that don’t want to set up their own sales force. A very consistent ROE generator. EPS has flatlined here, but he is optimistic that they are going to be getting back to a growth phase.

Consumer Products
0 0 0 0 0
0 comments

(A Top Pick July 4/16. Down 10.97%.) This in-licenses products and solutions from companies that are generally situated in Europe. They generally bring in in-licenses for companies that don’t want to set up their own sales force. A very consistent ROE generator. EPS has flatlined here, but he is optimistic that they are going to be getting back to a growth phase.

Consumer Products
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$7.950
Owned Owned
Unknown

HOLD
BioSyent Inc(RX-X) 

October 20, 2016

A bit tricky, because there is not necessarily a catalyst for earnings to really move in the near future. $9-$10 would be his more immediate target price. Extremely well-run. Very consistent ROE generator, and have been growing their earnings fabulously over the last 5 years or so. Have some new products they are going to be launching towards the end of 2017, which will be the impetus to see earnings and subsequently the stock to move higher. He likes this for the long-term.

Consumer Products
0 0 0 0 0
0 comments

A bit tricky, because there is not necessarily a catalyst for earnings to really move in the near future. $9-$10 would be his more immediate target price. Extremely well-run. Very consistent ROE generator, and have been growing their earnings fabulously over the last 5 years or so. Have some new products they are going to be launching towards the end of 2017, which will be the impetus to see earnings and subsequently the stock to move higher. He likes this for the long-term.

Consumer Products
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$8.520
Owned Owned
Yes

PAST TOP PICK
BioSyent Inc(RX-X) 

August 19, 2016

(A Top Pick July 4/16. Up 0.61%.) He still likes this. Recently came out with Q2 results which were quite good. Top line growth was about 17%. Very consistent ROE generators. Just announced 2 cardiology products they are going to be launching in Q3, which at peak revenue generation should increase revenues by 60%. Excellent management.

Consumer Products
0 0 0 0 0
0 comments

(A Top Pick July 4/16. Up 0.61%.) He still likes this. Recently came out with Q2 results which were quite good. Top line growth was about 17%. Very consistent ROE generators. Just announced 2 cardiology products they are going to be launching in Q3, which at peak revenue generation should increase revenues by 60%. Excellent management.

Consumer Products
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$8.300
Owned Owned
Yes

TOP PICK
BioSyent Inc(RX-X) 

July 4, 2016

A small growth company, very consistent ROE generator.  They recently announced licensing of two cardiology products that should increase revenue by 60% and they recently broke out of a trading range.

Consumer Products
0 0 0 0 0
0 comments

A small growth company, very consistent ROE generator.  They recently announced licensing of two cardiology products that should increase revenue by 60% and they recently broke out of a trading range.

Consumer Products
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$8.200
Owned Owned
Yes

BUY
BioSyent Inc(RX-X) 

March 7, 2016

Had been built around a single product that related to iron deficiency. They have taken fairly high levels of profitability and have been picking up other stuff, and a lot of those other drugs have taken time to get a sales channel. Now that we are into 2016, those other products are starting to contribute, so the dependency on a single drug is getting smaller and smaller. Stock had a huge run up, and got really overvalued. They put out a great set of results on Friday. ROE is still above 30%, and is trading at about 18X 2016 earnings. The stock had a correction and then stabilized at the $6.50-$7 level, and he thinks the stock is going to start to advance. Emerging as a nice, high quality stock.

Consumer Products
0 0 0 0 0
0 comments

Had been built around a single product that related to iron deficiency. They have taken fairly high levels of profitability and have been picking up other stuff, and a lot of those other drugs have taken time to get a sales channel. Now that we are into 2016, those other products are starting to contribute, so the dependency on a single drug is getting smaller and smaller. Stock had a huge run up, and got really overvalued. They put out a great set of results on Friday. ROE is still above 30%, and is trading at about 18X 2016 earnings. The stock had a correction and then stabilized at the $6.50-$7 level, and he thinks the stock is going to start to advance. Emerging as a nice, high quality stock.

Consumer Products
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$6.850
Owned Owned
Yes

PAST TOP PICK
BioSyent Inc(RX-X) 

December 23, 2015

(A Top Pick Dec 24/14. Down 31.61%.) Great company. Share price has not performed very well. They have delivered great results since then, but we have seen all this multiple contraction in the healthcare sector. Fairly narrowly focused around 1 drug. Its value is starting to get to the point where people are going to start to nibble. Be patient.

Consumer Products
0 0 0 0 0
0 comments

(A Top Pick Dec 24/14. Down 31.61%.) Great company. Share price has not performed very well. They have delivered great results since then, but we have seen all this multiple contraction in the healthcare sector. Fairly narrowly focused around 1 drug. Its value is starting to get to the point where people are going to start to nibble. Be patient.

Consumer Products
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$7.010
Owned Owned
Yes

PAST TOP PICK
BioSyent Inc(RX-X) 

October 19, 2015

(A Top Pick Dec 24/14. Down 31.71%.) This stock came down early in the year because of concerns about their over focus on a single product. Corrected earlier in the year and has just been trading sideways. Looks cheap. He expects it will bounce back with the rest of the sector.

Consumer Products
0 0 0 0 0
0 comments

(A Top Pick Dec 24/14. Down 31.71%.) This stock came down early in the year because of concerns about their over focus on a single product. Corrected earlier in the year and has just been trading sideways. Looks cheap. He expects it will bounce back with the rest of the sector.

Consumer Products
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$7.000
Owned Owned
Yes

BUY
BioSyent Inc(RX-X) 

June 30, 2015

Would rate this as a Buy, but not a strong Buy. He is comfortable that they can grow their profits over the next 3 years by 25%-30% per year. However, this company is narrowly focused on 1 or 2 products, and they need to diversify beyond that. He thinks they will get there. A good name to own at the $7.50-$8 level.

Consumer Products
0 0 0 0 0
0 comments

Would rate this as a Buy, but not a strong Buy. He is comfortable that they can grow their profits over the next 3 years by 25%-30% per year. However, this company is narrowly focused on 1 or 2 products, and they need to diversify beyond that. He thinks they will get there. A good name to own at the $7.50-$8 level.

Consumer Products
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$7.350
Owned Owned
Yes

PAST TOP PICK
BioSyent Inc(RX-X) 

May 11, 2015

(A Top Pick June 4/14. Up 15.41%.) This is smallish and conservative, but continues to improve its numbers. Continues to get its products, mostly iron related, into pharmacies all across Canada. He is confident they can continue to increase their product range.

Consumer Products
0 0 0 0 0
0 comments

(A Top Pick June 4/14. Up 15.41%.) This is smallish and conservative, but continues to improve its numbers. Continues to get its products, mostly iron related, into pharmacies all across Canada. He is confident they can continue to increase their product range.

Consumer Products
0 0 0 0 0
0 comments
Michael Smedley

Exec VP & , Morgan Meighan & Ass...

Price Price
$8.090
Owned Owned
Yes

BUY
BioSyent Inc(RX-X) 

May 6, 2015

The issue with this is that it is too dependent on a single product. When people started realizing how much of their earnings came from one product, it made him nervous. As it overshot up into that $11-$12 range, it got really extended. It has now checked back and he would rate it is a Buy again. He is pretty comfortable that over the next 2-3 years it will grow its top line and its bottom line at 30% per annum for the next 3 years. They now have a whole bunch of other new products that they have already launched and are starting to ramp up.

Consumer Products
0 0 0 0 0
0 comments

The issue with this is that it is too dependent on a single product. When people started realizing how much of their earnings came from one product, it made him nervous. As it overshot up into that $11-$12 range, it got really extended. It has now checked back and he would rate it is a Buy again. He is pretty comfortable that over the next 2-3 years it will grow its top line and its bottom line at 30% per annum for the next 3 years. They now have a whole bunch of other new products that they have already launched and are starting to ramp up.

Consumer Products
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$7.870
Owned Owned
Yes

BUY
BioSyent Inc(RX-X) 

March 24, 2015

Very steady, careful accumulator of products to market in Canada in the medical field. 

Consumer Products
0 0 0 0 0
0 comments

Very steady, careful accumulator of products to market in Canada in the medical field. 

Consumer Products
0 0 0 0 0
0 comments
Michael Smedley

Exec VP & , Morgan Meighan & Ass...

Price Price
$9.660
Owned Owned
Unknown

WEAK BUY
BioSyent Inc(RX-X) 

February 23, 2015

Likes the story but the valuation is a bit too high.  It is not that liquid of a stock.  Hard to buy in a fund, but okay for individual investors.  Prefers MLS-T.

Consumer Products
0 0 0 0 0
0 comments

Likes the story but the valuation is a bit too high.  It is not that liquid of a stock.  Hard to buy in a fund, but okay for individual investors.  Prefers MLS-T.

Consumer Products
0 0 0 0 0
0 comments
Peter Imhof

Vice Presi, AGF Investments Inc...

Price Price
$10.010
Owned Owned
Unknown

Showing 1 to 15 of 21 entries
Successfully Saved Company
Successfully Saved Company